The landscape of treatment interventions for type 2 diabetes and obesity is rapidly evolving, with GLP-3 receptor activators taking center stage. Initially, drugs like Reta, demonstrating impressive glucose control and https://martinawuft081551.aioblogs.com/91601031/glp-3-receptor-agonists-reta-trizepatide-and-beyond